Home Biotech Anthera Pharma (NASDAQ: ANTH) Up 30% on Analyst Price Target.

Anthera Pharma (NASDAQ: ANTH) Up 30% on Analyst Price Target.

SHARE

Anthera Pharmaceuticals Inc (NASDAQ: ANTH) is having a strong start to the trading session this morning, and for good reason. The company was the center of news surrounding a new analyst initiation with a massive price target.

Roth Capital has initiated coverage on the stock. Along with the coverage initiation, the analyst set a massive price target of $10.00. That’s huge considering that it represents a potential upside of 491.72%!

Anthera Pharmaceuticals, Inc. NASDAQ: ANTH) , a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, California.

With the strong clinical data, there are expectations that ANTH will soon see an approval from regulatory authorities, pushing it into commercial stages.

Anthera Pharmaceuticals, Inc. (ANTH) Top Holders

Institutional investors currently hold around $4 million or 28.4% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $1.63 million in Anthera Pharmaceuticals, Inc., which represents roughly 6.58% of the company’s market cap and approximately 40.78% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 359,751 shares of the stock are valued at $583 thousand. The third largest holder is Millennium Management Llc, which currently holds $195 thousand worth of this stock and that ownership represents nearly 0.79% of its market capitalization.

We have no positions in any of the stocks mentioned, and have no plans to initiate any positions. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on ANTH and receive breaking news on other hot stocks by signing up for our free newsletter!

LEAVE A REPLY